Safety of riociguat for chronic thromboembolic pulmonary hypertension (CTEPH): Interim data from a prospective non-interventional study in Japan

Conclusions: The AE profile of riociguat in clinical practice in Japan appears consistent with clinical trials globally and in Japan. The most common AEs are consistent with the vasodilating action of riociguat. Most common drug-related AEs, No. of patients (%)Hypotension40 (5.8)Headache19 (2.8)Gastroesophageal reflux disease8 (1.2)Dizziness8 (1.2)Diarrhoea6 (0.9)Abdominal discomfort6 (0.9)Peripheral oedema5 (0.7)Dyspepsia5 (0.7)Nausea5 (0.7)

Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Tanabe, N., Ogo, T., Hatano, M., Tazaki, Y., Sunaya, T., Saikawa, A., Sakaguchi, T. Tags: Pulmonary hypertension Source Type: research